Minerva Neurosciences (NERV) Long-Term Investments (2015 - 2017)

Minerva Neurosciences (NERV) posted Long-Term Investments of $5.0 million for Q4 2017, down 51.49% on a QoQ basis from $10.4 million in Q3 2017.

Minerva Neurosciences (NERV) Long-Term Investments (2015 - 2017) Analysis & Trends

Minerva Neurosciences' Long-Term Investments history runs 2 years deep, the most recent figure standing at $5.0 million for Q4 2017.

Quarterly Long-Term Investments changed N/A year-over-year to $5.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $5.0 million (changed N/A YoY) and the FY2017 annual result came in at $5.0 million, changed N/A from the prior year.
Long-Term Investments was $5.0 million for Q4 2017 at Minerva Neurosciences, down from $10.4 million in the prior quarter.
Across five years, Long-Term Investments topped out at $10.4 million in Q3 2017 and bottomed at $1.4 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Minerva Neurosciences	195.10 Mn	195.10 Mn	-	-

Download Data